Breast Cancer: FDA Revokes Avastin Approval

The U.S. Food and Drug Administration today announced it will revoke the approval of Avastin for breast cancer, citing a lack of evidence that the benefits outweigh the risks. Avastin was approved for metastatic breast cancer in February 2008 under the agency's accelerated approval program, which offers patients early access to promising drugs while confirmatory clinical trials are carried out. "Unfortunately the additional studies failed to confirm Avastin's initial promise," FDA...Full Story
Commenting on this article is closed.